Ultime notizie per THC Farmaceuticals (OTC:CBDG) Azioni

THC Farmaceuticals Inc is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology, and other medical disciplines.

THC FARMACEUTICALS INC by THC Farmaceuticals, Inc

THC Farmaceuticals Inc

Mark Yusko, the founder and CIO of Morgan Creek Capital, believes the ongoing Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally is <a href="https://www.benzinga.com/money/bitcoin-price-prediction">far from over</a>.
What Happened: Speaking as Bitcoin surpassed a new all-time high near $111,000, Yusko said the asset's upward trajectory is backed by deep structural forces and a fundamental shift in how the global economy treats money.
"This idea that we should be surprised that we keep making all-time highs? Of course we're going to make new all-time highs," Yusko <a href="https://www.youtube.com/live/z7qkIRX1GJQ">said</a>, pointing to the rapid devaluation of fiat currencies. "We printed 80% of all the dollars that ever existed in the last five years."
Unlike traditional assets like stocks and bonds, Yusko emphasized that Bitcoin's performance is not linked to GDP growth or inflation. 
"Bitcoin prices are determined by the technology itself, by adoption, particularly among young people, and by changes in fiat," he said, reiterating that Bitcoin is "so not correlated" with other asset classes over the long term.
Yusko called Bitcoin a modern form of money, superior to gold due to its portability and divisibility. 
"One Bitcoin is one Bitcoin," he added, highlighting that its value is not diluted over time. "It's like an ounce of gold. A single ounce of gold is still a single ounce of gold."
The bullish sentiment was echoed by other guests on the show. 
Dan, a technical analyst from The Chart Guys, noted that a golden cross, when the 50-day moving average crosses above the 200-day, just occurred, which has historically preceded parabolic advances. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45570094/anthony-scaramucci-says-thin-supply-is-driving-bitcoin-to-new-all-time-highs">Anthony Scaramucci Says Thin Supply Is Driving Bitcoin To New All-Time Highs</a>
"This asset wants to go," Dan said, describing current price momentum as "ideal."
While some observers are cautious, recalling previous failed breakouts, Yusko said the macroeconomic landscape supports further gains. 
He cited treasury auctions failing, uncontrolled interest rates in Japan, and ongoing inflation in Western economies as signals of systemic weakness in fiat-based systems. 
"There's a point at which a country loses control and you get hyperinflation," he warned.
Despite differing opinions on the immediate threat of hyperinflation, Yusko and fellow panelist Yago agreed that the only politically viable way out of the current debt trap is through currency devaluation. 
"You can't pay it back. You can't restructure it. You can't default on it. So you devalue it," Yusko said.
What&#8217;s Next: For Yusko, Bitcoin is not just an investment, it's protection against what he called the "dictator playbook": wealth concentration, inflation, and the erosion of civil liberties through financial repression.
He pointed out how other nations have already seen Bitcoin reach record highs locally due to collapsing currencies, including Venezuela, Turkey, and Argentina.
"Bitcoin is better than gold," Yusko said. "It's money that doesn't rely on the liabilities of governments and it's the foundation of a new financial system that's already here."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45567511/no-one-can-shut-down-bitcoin-says-impossible-cloud-founder">&#8216;No One Can Shut Down Bitcoin,&#8217; Says Impossible Cloud Founder</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

Bitcoin Rally Has Room To Run, Says Morgan Creek's Mark Yusko

Citigroup analyst Karen Holthouse initiates coverage on Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Neutral rating and announces Price Target of $78.

Price Target

Initiation

Analyst Ratings

Citigroup Initiates Coverage On Sysco with Neutral Rating, Announces Price Target of $78

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he <a href="https://www.benzinga.com/news/large-cap/25/05/45490992/vertiv-develops-power-solutions-in-sync-with-nvidias-ai-roadmap">likes Vertiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)</a>.
As per the recent news, on Monday, Vertiv announced its strategic alignment with Nvidia Corp.‘s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) vision for AI data centers, specifically the deployment of 800 VDC power architectures. Anticipating the demands of future AI deployments, including the NVIDIA Kyber and Rubin Ultra platforms, Vertiv's comprehensive 800 VDC power portfolio is slated for release in the second half of 2026.
Cramer said no to Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>), noting that there is &#8220;too much risk.&#8221;
Supporting his view, Medical Properties Trust reported a quarterly FFO of 14 cents per share on May 1, which missed the analyst consensus estimate of 15 cents per share. The company also reported quarterly sales of $223.80 million, which missed the analyst consensus estimate of $229.81 million.
The Mad Money host recommended owning Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) for the long term.
Lending support to his choice, Nucor posted better-than-expected earnings for the first quarter on April 28. The company reported quarterly earnings of 77 cents per share, which beat the analyst consensus estimate of 64 cents per share. The company reported quarterly sales of $7.83 billion, which beat the analyst consensus estimate of $7.23 billion.
Price Action:
<ul class="wp-block-list">
<li>Vertiv shares gained 0.6% to settle at $104.20 on Thursday.</li>
<li>Medical Properties Trust shares declined 1.3% to close at $4.56 during the session.</li>
<li>Nucor shares fell 0.9% to settle at $110.69 on Thursday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45562909/top-2-financial-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Financial Stocks That May Keep You Up At Night In May</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

NVDA

Jim Cramer Says Medical Properties Trust Has 'Too Much Risk,' Likes This Industrial Stock

Citigroup analyst Karen Holthouse initiates coverage on Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) with a Buy rating and announces Price Target of $121.

PFGC

Citigroup Initiates Coverage On Performance Food Gr with Buy Rating, Announces Price Target of $121

President Donald Trump&#8217;s threat to impose a sweeping 50% tariff on all European Union imports starting June 1 sparked a broad selloff across European markets Friday, triggering fears of a transatlantic trade war just as global <a href="https://www.benzinga.com/topic/tariffs">growth faces renewed pressure.</a>
In a post on Truth Social, Trump said the EU&#8217;s "powerful Trade Barriers, VAT Taxes, ridiculous Corporate Penalties, Non-Monetary Trade Barriers, Monetary Manipulations, unfair and unjustified lawsuits against American Companies" were to blame for an annual trade deficit exceeding $250 billion, which he called "totally unacceptable."
The proposed tariff would exempt goods manufactured in the United States, potentially creating sharp distortions for EU-based exporters and global supply chains.
<h3 class="wp-block-heading">European Benchmarks Tumble</h3>
The fallout was immediate in markets. The Euro STOXX 50 index – as closely tracked by the iShares MSCI Eurozone ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EZU#NYSE">EZU</a>) – dropped 3%, Italy's FTSE MIB sank 2.9%, France's CAC 40 lost 2.6% and Spain's IBEX 35 fell 2.2%. 
Germany's DAX, as tracked by the iShares MSCI Germany Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWG#NYSE">EWG</a>), which is home to many export-heavy firms, slid 2.3%.
Financial stocks bore the brunt of the decline, with Deutsche Bank AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) falling 6.1%, Société Générale SA (OTCPK: SCGLY) down 5.3% and Banco Bilbao Vizcaya Argentaria SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBVA#NYSE">BBVA</a>) sliding 5%.
 Industrial and luxury exporters also came under heavy pressure, including Bayerische Motoren Werke AG (OTCPK: BMWYY), or BMW (−4.5%), UniCredit SpA (OTCPK: UNCRY) (−4.5%) and EssilorLuxottica SA (OTCPK: ESLOY) (−4.2%).
<h3 class="wp-block-heading">Export Exposure To US Trade Is Key</h3>
The tariff threat has placed a spotlight on European companies heavily reliant on U.S. revenues.
In Germany, Adidas AG (OTCPK: ADDYY) derives roughly a third of its revenue from the United States, while SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) generates about 40% of its turnover from North America. 
Chipmaker Infineon Technologies AG (OTCPK: IFNNY) is also significantly exposed due to its automotive and electronics customers.
French luxury and tech firms are equally at risk. LVMH Moët Hennessy Louis Vuitton SE (OTCPK: LVMUY) earns close to 25% of its revenue in the U.S., while Dassault Systèmes SE (OTCPK: DASTY) has a strong footprint in North American enterprise software. Hermès International SA (OTCPK: HESAY) pulls about 20-25% of its sales from the American market.
Italian brands like Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>), with over 30% of sales from the U.S., and EssilorLuxottica SA (OTCPK: ESLOY), which owns Oakley and Ray-Ban, are also vulnerable. 
In the Netherlands, tech heavyweight ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) earns about 20-25% of revenue from the U.S., and Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) maintains a major healthcare business across North America.
<h3 class="wp-block-heading">EU Retaliation Risk Grows For US Stocks</h3>
For U.S. corporations with heavy exposure to Europe—particularly in tech, autos, agriculture and aviation—the economic consequences could be significant if the European Union responds in kind.
The 2018 EU countermeasures to Trump&#8217;s steel tariffs included duties on motorcycles, bourbon and orange juice—strategic hits on U.S. swing-state exports.
EU officials may also revisit tech taxation disputes, where U.S. firms like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) are already under regulatory scrutiny.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45584696/trump-threatens-tim-cook-to-manufacture-iphones-in-the-us-or-face-at-least-25-tariffs">Trump Threatens Tim Cook To Manufacture iPhones In US Or Face &#8216;At Least 25%&#8217; Tariffs: AAPL Stock Slides Over 3% In Premarket </a></li>
</ul>
Photo Courtesy: Joshua Sukoff On Shutterstock.com

Analyst Color

Macro Economic Events

Sector ETFs

Eurozone

Econ #s

Economics

ETFs

AAPL

ADDYY

ASML

BBVA

BMWYY

DASTY

ESLOY

GOOGL

HESAY

IFNNY

LVMUY

MSFT

RACE

SCGLY

UNCRY

Trump Tariff Threat Hits Europe: Stocks Sink As 50% Duties Loom

WIIM

Analog Devices shares are trading lower after Benchmark cut its price target on the stock from $275 to $260. Also, Needham reiterated a Hold rating.

Jim Lebenthal of Cerity Partners named Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) as his final trade on CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/22/final-trades-delta-air-lines-mercadolibre-toast-and-the-iye.html">Halftime Report Final Trades</a>,&#8221; adding that people are flying and growth estimates <a href="https://www.benzinga.com/quote/DAL/analyst-ratings" target="_blank" rel="noopener">will</a><a href="https://www.benzinga.com/quote/DAL/analyst-ratings"> start going back higher</a>.
UBS analyst Thomas Wadewitz supported his view on Monday by upgrading Delta Air Lines from Neutral to Buy and raising the price target from $46 to $66.
Shannon Saccocia, chief investment officer of NB Private Wealth, said the iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) is undervalued because it is priced in with a lot of negative news.
Supporting her view, Paycom Software, on May 7, reported better-than-expected first-quarter earnings and sales.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova, senior managing director for Virtus Investment Partners, said MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) is the best consumer discretionary stock.
Adding support to his choice, MercadoLibre, on May 7, reported quarterly earnings of $9.74 per share which beat the analyst consensus estimate of $8.03 per share. The company reported quarterly sales of $5.93 billion which beat the analyst consensus estimate of $5.51 billion.
Joshua Brown, CEO of Ritholtz Wealth Management, named Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) his final trade.
Supporting his view, BMO Capital analyst Rufus Hone maintained Toast with an Outperform rating on May 12 and raised the price target from $44 to $45.
Price Action:
<ul class="wp-block-list">
<li>Delta Air Lines shares gained 0.5% to close at $48.50 on Thursday.</li>
<li>Toast shares fell 0.4% to close at $42.68 on Thursday.</li>
<li>MercadoLibre gained 0.2% to settle at $2,606.01 during Thursday's session.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45562909/top-2-financial-stocks-that-may-keep-you-up-at-night-in-may"> Top 2 Financial Stocks That May Keep You Up At Night In May</a></li>
</ul>
Photo: Shutterstock

iShares Dow Jones US Energy Sector Index Fund

MELI

TOST

Toast, Delta Air Lines, MercadoLibre And More On CNBC's 'Final Trades'

Maxim Group analyst Jason McCarthy downgrades Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) from Buy to Hold.

Downgrades

CTXR

Maxim Group Downgrades Citius Pharmaceuticals to Hold

IMNN

IMUNON shares are trading higher after the company announced new data from its Phase 2 OVATION 2 Study of IMNN-001.

USA Building Permits For April 1.422M Vs 1.412M Est.; 1.467M Prior

USA Building Permits (MoM) For April -4.0% Vs -4.7% Est.; 0.5% Prior

Leerink Partners analyst Joseph Schwartz upgrades Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) from Market Perform to Outperform and raises the price target from $4 to $12.

Upgrades

FULC

Leerink Partners Upgrades Fulcrum Therapeutics to Outperform, Raises Price Target to $12

BKNG moves up 1.1% on a day the broad market was flat
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/22205109/Screenshot-2025-05-22-at-4.47.39%E2%80%AFPM-974x1024.png" alt="" class="wp-image-13313" /></figure>
Today, Booking Holdings Inc.(BKNG)&nbsp;experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 09:50AM on May 22nd, a significant trading signal occurred for Booking Holdings Inc., (BKNG) as it demonstrated a Power Inflow at a price of $5296.03. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Booking&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Booking's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BKNG, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a> which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $5296.03. The returns on the High price ($5351.80) and Close price ($5341.91) after the Power Inflow are 1.1% and 0.87%, respectively. This result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

Technicals

Opinion

Signals

BKNG

Booking Shares Climb 1.1% After Key Signal

ROST

Ross Stores shares are trading lower after the company issued Q2 EPS guidance below estimates.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fastriatx.com%2F&amp;esheet=54259095&amp;newsitemid=20250523411051&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=b6399fb1ae2bead8534501a0ab8c6dfe">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025.
Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from the Phase 1a and Phase 1b/2 trials of navenibart in a presentation titled, "Navenibart for Hereditary Angioedema (HAE): Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trial." The presentation will take place at 2:45pm CET on Saturday, May 31 at the Ensana Thermal Hotel Margitsziget in Budapest.

ATXS

Astria Therapeutics To Present Safety And Efficacy Data From Phase 1a And Phase 1b/2 Trials Of Navenibart At C1 Inhibitor Deficiency And Angioedema Workshop

<a href="https://www.cda-amc.ca/trastuzumab-deruxtecan-2" title="https://www.cda-amc.ca/trastuzumab-deruxtecan-2">https://www.cda-amc.ca/trastuzumab-deruxtecan-2</a>

Biotech

General

Canada's Drug Agency Issues AstraZeneca's Enhertu Time-Limited Reimbursement Recommendation

Dan Morehead, founder and CEO of Pantera Capital on Friday said <a href="https://www.benzinga.com/25/05/45560419/trumps-crypto-czar-david-sacks-foresees-stablecoin-bill-generating-trillions-for-us-treasury-practically-overnigh">the crypto industry</a> is poised to see a surge of public offerings, with companies like Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) and Figure among those preparing to go public in the coming months.
What Happened: His <a href="https://www.cnbc.com/video/2025/05/21/pantera-capital-ceo-expects-wave-of-crypto-companies-to-go-public-in-next-6-months.html">comments</a> come amid what he described as a "flipping" of the U.S. regulatory environment, from a hostile stance to one that is now either "positive or at least neutral."
Morehead attributed this shift to multiple policy developments, including the SEC's rollback of Staff Accounting Bulletin 121, and new OCC guidance enabling banks to interact more directly with blockchain infrastructure. 
Combined, he said, these actions are unlocking long-constrained potential. 
"There are a lot of great companies that maybe should have gone public a few years ago," Morehead said. "In the next six months you're going to see a wave of great companies like Circle and Figure go public."
The renewed interest in U.S. capital markets for crypto is further underscored by strong demand from public investors. 
"MicroStrategy and other coin-based stocks prove people really want to invest in blockchain companies," he added.
Morehead emphasized this is not a short-term spike, but rather the beginning of a broader trend. 
"All of these companies have been kind of stuck in the pipe for the last two or three years," he said. "Now that they&#8217;re going public and each are going public today, it's trading up 35%, encourages other companies to go public. So I think it&#8217;s a big new trend."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45572374/xrp-dogecoin-shiba-inu-waiting-to-pump-they-dominate-mindshare-they-can-lead-in-culture-expert-says">XRP, Dogecoin, Shiba Inu Waiting To Pump: &#8216;They Dominate Mindshare, They Can Lead In Culture,&#8217; Expert Says</a>
Why It Matters: Pantera's optimism also stems from the rise of real-world assets on the blockchain, particularly in areas like stablecoins, tokenized treasuries, and on-chain mortgages.
He pointed to Pantera-backed projects such as Ondo Finance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ONDO</a>) and Figure, noting that Figure has already issued $40 billion worth of mortgages on blockchain rails, shaving off "over 100 basis points of friction."
When asked what further developments are needed to accelerate industry growth, Morehead highlighted regulatory clarity. 
"Uncertainty in the U.S. has driven innovation offshore," he said, noting that many companies previously relocated to jurisdictions like Singapore and the UAE due to hostility at home.
With the U.S. now appearing more open to blockchain innovation, he expects talent and capital to flow back.
Pantera is also actively participating in policy conversations in Washington, according to Morehead. "We're involved in a couple industry think tanks that advise the government. It's very important that blockchain happens in the U.S. rather than offshore."
As more companies up-list from international exchanges such as the TSX to U.S. markets, Morehead views this as a reversal of previous trends. "The U.S. has really been unique. Most countries have been neutral. Now the U.S. is going from being antagonistic to positive, and that helps people want a base in the U.S."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45571765/kraken-to-launch-247-tokenized-stock-trading-for-global-users-via-solana">Kraken To Launch 24/7 Tokenized Stock Trading For Global Users Via Solana</a></li>
</ul>
Image: Shutterstock

$ONDO

$USDC

Pantera CEO Predicts Surge In Crypto IPOs As US Regulatory Tone Turns Favorable

PicoCELA Inc. ("PicoCELA" or the "Company"), a Tokyo-based provider of enterprise wireless mesh solutions, today announced the pricing of a best-efforts public offering (the "Offering") of 6,100,000 American Depositary Shares ("ADSs") at a public offering price of $0.30 per ADS. The Company expects to receive aggregate gross proceeds of $1,830,000, before deducting placement agent commissions and other offering expenses. Each ADS represents one common share of the Company.
The Offering is expected to close on or about May 27, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use approximately 70% of the net proceeds from the Offering for working capital and general corporate purposes and approximately 30% for product development and research.

PCLA

PicoCELA Prices Best-Efforts Public Offering Of 6.1M ADSs At $0.30 Each, Targeting $1.83M In Gross Proceeds

JP Morgan analyst Tami Zakaria upgrades Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) from Neutral to Overweight and raises the price target from $225 to $277.

JP Morgan Upgrades Waste Management to Overweight, Raises Price Target to $277

Data show continuous&nbsp;clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group
Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years
Phase 2 OVATION 2 Study results also published in peer-reviewed journal Gynecologic Oncology
LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gjJV-8pq5g3oh1gh2jUxuoxJ0F5LPAG3SU7issIrNRZCETVe_q2IlrAJcaJ5wQ5-9ZsXI4EUNHnps6gnEtaM-VqHf2_SdhwGIezCyprWiKe7JdIggh4sV23Y5iUqugYpLSEcgUXXzzFMYh2cT48PtMnU7hmhss-w0LiVOW6CIhcMXGfJlLqq14KIi5URF4Vmpp321Ua074W-y5CIsq-DCtYrRt1pPPODxGRibgtPD9pWkSMHsOUVo9W9Oq6QMejCDS-SOkTmorkYHd6Qvvcawbs5RAdw2yLVRM83xqb3XSegDpZHVnnhEloZA9JHP9oZnWOZ24q5NuOhA6e4XpE587QHr6nO3mo04hqJGhreX00=">IMUNON</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced new positive data from the Company's Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer. Results are being highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 - June 3, 2025, in Chicago, Illinois and virtually, and are also being published simultaneously in the peer-reviewed journal Gynecologic Oncology.
Based on the highly encouraging Phase 2 OVATION 2 Study results and following alignment with the U.S. Food and Drug Administration (FDA), IMUNON recently initiated the first two sites for its pivotal Phase 3 OVATION 3 Study of IMNN-001 in newly diagnosed advanced ovarian cancer.

IMUNON To Present New Data From Phase 2 OVATION 2 Study Of IMNN-001, Investigational Therapy For Treatment Of Advanced Ovarian Cancer At 2025 ASCO Annual Meeting

THC Farmaceuticals

Comments

THC Farmaceuticals

Notizie

Ultime notizie per THC Farmaceuticals (OTC:CBDG) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO